Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study aimed to estimate the value of urine prostate specific antigen (uPSA) as a marker for benign prostatic hyperplasia (BPH) but reported no new clinical findings.

This study observed that the degradation product PTeCA significantly increased in hair treated with oxidative cosmetics, suggesting it could be a reliable marker for detecting such treatments, with a proposed PTCA cut-off value using PTeCA as the gold standard.

The researchers concluded that after the 2013 EMA recommendation, there was an overall reduction in CPA/EE prescriptions, but no substantial change in patient diagnoses or potential concurrent hormonal contraceptive use.

This study found that women with polycystic ovary syndrome had significantly higher levels of prostate-specific antigen, which positively correlated with testosterone levels, the LH/FSH ratio, and hirsutism severity.

This review summarizes NCCN guidelines for prostate cancer early detection, focusing on strategies to maximize detection of potentially curable cases while minimizing unnecessary procedures, but it reports no new clinical findings.

This study observed some differences in clinical outcomes when comparing CPA with spironolactone, flutamide, and finasteride, but no differences with other therapies, possibly due to small study size and non-standardized assessments; adverse effects could not be fully compared across treatments.

This survey found support among BAAPS members for using procedure-specific consent forms to improve clarity and consistency in patient information for aesthetic procedures.

This report from a consensus meeting concluded that while 5-alpha reductase inhibitors are beneficial for BPH treatment and prostate cancer risk reduction, their role in clinical practice should be more widely integrated into prostate management guidelines.

In this study, ovarian SAHA was found to be independently associated with a more insulin-resistant profile and increased risk of glucose abnormalities in women with PCOS, beyond common risk factors.

This study reports two cases where localized prostate cancer with low PSA levels was incidentally detected through CT scans performed for other medical reasons.

In this study, a treatment regimen combining cyproterone acetate and ethinyl estradiol significantly improved acne and seborrhoea in most women after three months, but had varied effects on hirsutism and alopecia.

This literature review discusses the need for a clinical practice guideline to help Canadian Nurse Practitioners in diagnosing and managing PCOS, noting its complexity and lack of existing guidelines.

This study found that females exposed to high cumulative doses of cyproterone acetate had a 6–20 fold increased risk of developing meningiomas compared to those on lower doses.

Clear definitions and strategies are needed to manage long-term COVID-19 symptoms effectively.

This study found that the oral Janus kinase inhibitor CP-690,550 has a direct effect on reducing pruritus in patients with psoriasis, independent of clinician-assessed improvements in psoriasis severity.

This study found that 10.3% of female high school students in Islamabad screened positive for PCOS, with associations including irregular menstrual cycles and higher BMI among those testing positive.

This study found that serum PSA levels and %fPSA have limited diagnostic capability in distinguishing prostate cancer, suggesting a need for new, more specific and sensitive markers.

In this study, researchers found that shorter CA repeats in the ERbeta gene are correlated with PSA expression, and PSA immunoexpression is associated with increased disease-free survival in breast cancer.

This policy brief reports that post-drug syndromes like Post-Finasteride Syndrome are largely overlooked in current pharmacovigilance systems, which prioritize acute drug reactions, resulting in inadequate recognition and management of persistent medication-induced conditions.

This study concluded that incorporating the percentage of free PSA and urinary markers improves the accuracy of determining the need for prostate biopsy.

This study observed that although 5-alpha-reductase inhibitors reduce PSA density in patients on active surveillance for prostate cancer, those who progress to more serious disease still show higher PSA densities, suggesting these inhibitors accentuate differences in clinically significant cases.

This study found that IsoPSA's ability to detect both any prostate cancer and clinically actionable prostate cancer remains unaffected by medications like 5-ARIs and α-blockers, which are commonly used to treat benign prostatic hyperplasia symptoms.

This policy brief highlights that post-drug syndromes remain under-recognized in pharmacovigilance, leading to inadequate risk assessments and patient care. It identifies systemic failures in current frameworks and recommends actions to improve long-term drug safety monitoring and education, affecting public health outcomes significantly.

This policy brief found that post-drug syndromes are under-recognized in current pharmacovigilance systems, leading to inadequate risk assessments and prolonged patient harm from persistent drug-induced conditions.

This randomized pilot study suggests that finasteride may benefit some men with category IIIA chronic pelvic pain syndrome, although it is not recommended as monotherapy unless benign prostatic hyperplasia is also present.

Systematic end-of-trial biopsies are the most reliable way to assess outcomes.

This study found that finasteride does not increase the risk of high-grade prostate cancer but instead improves the prostate-specific antigen test's sensitivity to detect such cancers.

This study reported that 12% of female Qassim University students had been diagnosed with PCOS, with misconceptions about the condition and treatments observed despite high awareness.

This study found that in a sample of girls and adolescents aged 15–24 years, the prevalence of PCOS was 22.5% according to the Rotterdam criteria.